Table of Contents 2
List of Tables 4
List of Figures 5
MacroGenics, Inc. Spshot 6
MacroGenics, Inc. Overview 6
Key Information 6
Key Facts 6
MacroGenics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
MacroGenics, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combition Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combition Treatment Modalities 16
MacroGenics, Inc. - Pipeline Products Glance 17
MacroGenics, Inc. - Late Stage Pipeline Products 17
Phase III Products/Combition Treatment Modalities 17
MacroGenics, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combition Treatment Modalities 18
Phase I Products/Combition Treatment Modalities 19
MacroGenics, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combition Treatment Modalities 20
MacroGenics, Inc. - Drug Profiles 21
margetuximab 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
teplizumab 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
enoblituzumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MGD-006 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MGD-007 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MGD-009 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MGD-010 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MGA-012 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MGD-013 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MGD-014 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclol Antibodies to Target DR5 for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclol Antibodies to Target EphA2 and CD3 for Breast Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclol Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclol Antibodies to Target ROR1 and CD3 for Oncology 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Monoclol Antibody Conjugate to Target B7-H3 for Oncology 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MacroGenics, Inc. - Pipeline Alysis 41
MacroGenics, Inc. - Pipeline Products by Target 41
MacroGenics, Inc. - Pipeline Products by Route of Administration 43
MacroGenics, Inc. - Pipeline Products by Molecule Type 44
MacroGenics, Inc. - Pipeline Products by Mechanism of Action 45
MacroGenics, Inc. - Recent Pipeline Updates 47
MacroGenics, Inc. - Dormant Projects 54
MacroGenics, Inc. - Company Statement 55
MacroGenics, Inc. - Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60